MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR Prime Standard Segment TecDAX) and Wacker Chemie AG are intensifying their cooperation in the use of WACKER's prokaryotic secretion technology The two companies have signed a new agreement precisely defining areas of use and production limits under which MorphoSys will continue to use the secretion system on a research scale Tag Archives: Wacker Chemie AG Wacker Chemie AG to acquire Dutch site for manufacturing biopharmaceuticals live microbial products and vaccines from SynCo Bio Luxembourg S r l Posted on 23 April 2018 by EuropaWire PR Editors WACKER TAKES OVER SYNCO BIO PARTNERS OF AMSTERDAM CAPACITY OF ACQUIRED FERMENTATION PLANT FOR PHARMACEUTICAL ACTIVES TOTALS SOME 2 000 LITERS – WACKER

Board of Directors

Senior Vice-President at Wacker Chemie AG (2001–2002) Various Marketing Sales Strategic Planning and Global Management Positions with: Vantico (2000–2001) Ciba-Geigy / Ciba Specialty Chemicals (1994–2000) Dow Chemicals Europe (1981–1993) Serono-Hypolab (1979–1981) Download portrait Christoph Mder Independent member of the Board of Directors of Lonza Group Ltd (since April 2016

Wacker strengthens its pharmaceutical-protein business and buys Dutch biotech plant 18-Apr-2018 Biotechnology | Contract Manufacturing | Finance Wacker Chemie AG has acquired a Dutch site to manufacture biopharmaceuticals live microbial products and vaccines plus the associated business from SynCo Bio Luxembourg Srl

Some of the market players in the microbial protein production service market includes Wacker Chemie AG Icosagen Sino Biological GenScript LP3 Labs Lonza Biomatik GenWay Biotech Inc Olympic Protein Technologies Amid Biosciences and many others The report offers a comprehensive evaluation of the market It does so via in-depth

WACKER | 49 709 abonns sur LinkedIn | CREATING TOMORROW'S SOLUTIONS | WACKER is a leading player and one of the world's most research-intensive chemical companies Our range of highly developed specialty products extends from silicones and polymeric binders and additives for a number of different industrial sectors to bio-engineered pharmaceutical actives (biologics) and hyperpure

Wacker Chemie has developed a patented E coli strain for extracellular production of pharmaceutical proteins The system transports proteins in functional conformation through the outer cell membrane into the culture medium This proprietary technology provides the basis for cost-efficient industrial-scale production of ultra-pure active biopharmaceutical ingredients

Wacker buys SynCo's Dutch biotechnology plant

Wacker Chemie AG a globally-active chemical company has acquired a Dutch site for manufacturing biopharmaceuticals live microbial products and vaccines plus the associated business from SynCo Bio Luxembourg S r l For Wacker maintaining SynCo's existing customer relationships is a top priority Moreover Wacker is keeping on SynCo's employees Both parties have agreed not to

Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals live microbial products and vaccines plus the associated business from SynCo Bio Luxembourg S r l For WACKER maintaining SynCo's existing customer relationships is a top priority Moreover WACKER

Munich and Amsterdam April 17 2018 – Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals live microbial products and vaccines plus the associated business from SynCo Bio Luxembourg S r l The Munich-based chemical company announced the acquisition today For WACKER maintaining SynCo's existing customer relationships is a top priority Moreover WACKER

Wacker Chemie has developed a patented E coli strain for extracellular production of pharmaceutical proteins The system transports proteins in functional conformation through the outer cell membrane into the culture medium This proprietary technology provides the basis for cost-efficient industrial-scale production of ultra-pure active biopharmaceutical ingredients

WACKER | 49 714 followers on LinkedIn | CREATING TOMORROW'S SOLUTIONS | WACKER is a leading player and one of the world's most research-intensive chemical companies Our range of highly developed specialty products extends from silicones and polymeric binders and additives for a number of different industrial sectors to bio-engineered pharmaceutical actives (biologics) and hyperpure

Wacker Chemie AG Press and Information Nadine Baumgartl Phone +49 (0) 89 6 2791 604 Notes to editors About Pieris AG Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins a novel class of targeted human proteins designed to diagnose and treat serious human disorders Exploiting extensive know-how in protein engineering as part of a broad

Wacker Chemie AG (Munich Germany) is investing in its production facilities for biologics LMPs (live microbial products) and vaccines at its Amsterdam site Projects include the construction of a new fermentation line with a volume of 1 500 liters as well as the setting up of new cleanroom structures in the 270-L fermentation line The investment price is a mid-double-digit million-euro amount

In a recent letter Wacker Biotech announced its swift progress in its integration of Scil Proteins Production following its acquisition in November 2013 Since then Scil Proteins Production has ceased to exist as an independent company and is now listed under the commercial register entry for Wacker Biotech having officially merged with them All rights and obligations

PRESS RELEASE

Wacker Chemie AG Hanns-Seidel-Platz 4 81737 Munich Germany Number 4 LIBATEC: WACKER Launches New Brand for Production Technology for Live Microbial Products (LMPs) Munich / Amsterdam March 3 2020 – Wacker Biotech is now marketing its technology platform for developing and manufacturing Live Microbial Products (LMPs) under the brand name LIBATEC

Live microbial products represent a promising new class of actives offering innovative therapies for serious illnesses and new vaccines against diseases such as cholera Industry experts forecast an average growth rate of 13 8 percent for the global biologics market until 2025 About Wacker Biotech Wacker Biotech and Wacker Biotech B V are full-service contract manufacturers of

Bright Outlook for Microbial Cysteine Now that WACKER produces cysteine itself it no longer relies on the contracting party that had previously supplied the amino acid The company has also built up its biotech expertise and increased its added value "Integration of cysteine production was a logical step The fact that we successfully completed the project together with our team and

WACKER Launches New Brand fre jul 10 2020 14:36 CET Silicones for Products and Sanitary Paper are Now Sold Under the Name LIOSIL Munich July 10 2020 – Munich-based chemical company WACKER is bundling its high-quality silicone additives for the and personal care industry under a new brand name Silicone fluids and emulsions for textile and surface care products

Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals live microbial products and vaccines plus the associated business from SynCo Bio Luxembourg S r l The Munich-based chemical company announced the acquisition today For WACKER maintaining SynCo's existing customer relationships is a top priority Moreover WACKER is keeping on SynCo's employees Both

WACKER ascertained the long term importance of bacterial systems at an early stage: Wacker Biotech is now a contract producer of biologics with over 25 years' experience in microbial systems The company which has been a one hundred percent subsidiary of the global company Wacker Chemie AG since 2005 was established in the year 1999 with the name ProThera in Jena (Thuringia)

WACKER Lifts Earnings Markedly in Q1 2020 and Refrains from Providing Full-Year Forecast Due to Corona Pandemic tor apr 30 2020 13:47 CET GROUP SALES FOR Q1 2020 TOTAL €1 20 BILLION 3 PERCENT LOWER YEAR OVER YEAR BUT UP 4 PERCENT VERSUS A QUARTER AGO EBITDA OF €174 MILLION RISES BY 23 PERCENT YEAR OVER YEAR AMID HIGHER PLANT